J Kelly

Summary

Affiliation: SmithKline Beecham Pharmaceuticals
Country: USA

Publications

  1. ncbi Warfarin pharmacodynamics unaffected by cilomilast
    J Kelly
    GlaxoSmithKline, New Frontiers Science Park, Third Ave, Harlow, CM19 5AW Essex, UK
    Ann Pharmacother 35:1535-9. 2001
  2. ncbi Cilomilast (Ariflo) does not potentiate the cardiovascular effects of inhaled salbutamol
    R D Murdoch
    Clinical Pharmacology, GlaxoSmithKline, Harlow, UK
    Pulm Pharmacol Ther 15:521-7. 2002

Detail Information

Publications2

  1. ncbi Warfarin pharmacodynamics unaffected by cilomilast
    J Kelly
    GlaxoSmithKline, New Frontiers Science Park, Third Ave, Harlow, CM19 5AW Essex, UK
    Ann Pharmacother 35:1535-9. 2001
    ..To demonstrate a lack of effect of steady-state concentrations of cilomilast, a new oral phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease, on warfarin-induced anticoagulation...
  2. ncbi Cilomilast (Ariflo) does not potentiate the cardiovascular effects of inhaled salbutamol
    R D Murdoch
    Clinical Pharmacology, GlaxoSmithKline, Harlow, UK
    Pulm Pharmacol Ther 15:521-7. 2002
    ..Both agents were well tolerated. In conclusion, the pharmacodynamic effects associated with salbutamol inhalation were unaffected by co-administration of cilomilast...